Management to Host Conference Call Monday, November 14, 2016 at 4 pm
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT, www.provectusbio.com),
a clinical-stage oncology and dermatology biopharmaceutical company
("Provectus" or the "Company”), today announced its financial results
for the quarter ended September 30, 2016.
Third Quarter Results and Balance Sheet Highlights
Our cash and cash equivalents were $5,178,076 at September 30, 2016,
compared with $4,891,313 at June 30, 2016. As of December 31, 2015, cash
and equivalents were $14,178,902.
Shareholders' equity at September 30, 2016 was $5,309,712. This compares
to shareholders' equity of $9,140,166 at June 30, 2016, and $16,316,941
as of December 31, 2015.
For additional information regarding Provectus' results of operations
and financial condition for the third quarter ended September 30, 2016,
please see Provectus' Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on November 9, 2016.
Management will host its 2016 third quarter business update conference
call on Monday, November 14, 2016 at 4 pm Eastern Standard Time.
Management will provide a business update on PV-10 and PH-10 to the
investment community and answer questions from investors.
Those who wish to participate in the conference call may telephone
877-407-4019 from the U.S. International callers may telephone
201-689-8337 approximately fifteen minutes before the call. A webcast
will also be available at www.provectusbio.com.
A digital replay will be available by telephone approximately two hours
after the completion of the call until March 4, 2017 and may be accessed
by dialing 877-660-6853 from the U.S. or 201-612-7415 for international
callers, and using the Conference ID # 13648197.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating new therapies for the
treatment of skin cancer, liver cancer and breast cancer. Provectus’
investigational oncology drug, PV-10, is an ablative immunotherapy under
investigation in solid tumor cancers. The Company has received orphan
drug designations from the FDA for its melanoma and hepatocellular
carcinoma indications. PH-10, its topical investigational drug for
dermatology, is undergoing clinical testing for psoriasis and atopic
dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy
for metastatic melanoma, and of PH-10 as a topical treatment for atopic
dermatitis and psoriasis. Information about these and the Company's
other clinical trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company's
website at www.provectusbio.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking
statements" as defined under U.S. federal securities laws. These
statements reflect management's current knowledge, assumptions, beliefs,
estimates, and expectations and express management's current views of
future performance, results, and trends and may be identified by their
use of terms such as "anticipate," "believe," "could," "estimate,"
"expect," "intend," "may," "plan," "predict," "project," "will," and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2015, as supplemented by those
described in Part II, Item 1A of our Quarterly Report on Form 10-Q for
the quarter ended September 30, 2016) and the following:
our determination, based on guidance from the FDA, whether to proceed
with or without a partner with the fully enrolled phase 3 trial of
PV-10 to treat locally advanced cutaneous melanoma and the costs
associated with such a trial if it is necessary to complete (versus
interim data alone);
our determination whether to license PV-10, our investigational drug
product for melanoma and other solid tumors such as cancers of the
liver, if such licensure is appropriate considering the timing and
structure of such a license, or to commercialize PV-10 on our own to
treat melanoma and other solid tumors such as cancers of the liver;
our ability to license PH-10, our investigational drug product for
dermatology, on the basis of our phase 2 atopic dermatitis and
psoriasis results, which are in the process of being further developed
in conjunction with mechanism of action studies;
our ability to raise additional capital if we determine to
commercialize PV-10 and/or PH-10 on our own, although our expectation
is to be acquired by a prospective pharmaceutical or biotech concern
prior to commercialization; and
our ability to raise capital through our proposed rights offering.